Biosimilars Market worth $6.22 Billion by 2020
This presentation is the property of its rightful owner.
Sponsored Links
1 / 2

Biosimilars Market Size Estimation PowerPoint PPT Presentation


The report segments the market on the basis of product, application, and region. Among various product types, the recombinant nonglycosylated protein segment is expected to account for the largest share of the market in 2015.

Download Presentation

Biosimilars Market Size Estimation

An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -

Presentation Transcript


Biosimilars market size estimation

Biosimilars Market worth $6.22 Billion by 2020

The report “Biosimilars Market by Product (Recombinant Non-Glycosylated Proteins (Insulin,

Filgrastim, Interferons, rHGH), Glycosylated (Monoclonal Antibodies, EPO), Peptides (Glucagon,

Calcitonin)) & Application (Oncology, Blood Disorders) - Global Forecast to 2020” analyzes and

studies the major market drivers, restraints, opportunities, and challenges in North America, Europe, Asia-

Pacific, and the Rest of the world (RoW).

http://www.marketsandmarkets.com/Market-Reports/biosimilars-40.html

The global biosimilars market is expected to reach $6.22 Billion by 2020 from $2.29 Billion in 2015, at a

CAGR of 22.1% from 2015 to 2020.

The report segments the market on the basis of product, application, and region. Among various product

types, the recombinant nonglycosylated protein segment is expected to account for the largest share of

the market in 2015. However, the recombinant glycosylated protein segment is expected to grow at the

highest CAGR during the forecast period.

A number of factors such as growing pressure to curtail healthcare expenditure, growing demand of

biosimilar drugs due to their cost effectiveness, rising incidences of various diseases, increasing number

of off-patented drugs, positive outcome in the ongoing clinical trials, and rising demand for biosimilars in

different therapeutic applications such as rheumatoid arthritis and blood disorders are propelling the

growth of the global market. On the other hand, high manufacturing complexities and costs, stringent

regulatory requirements in countries, and innovative strategies by biologic drug manufacturers to restrict

entry of new players are restricting the growth of the global market.

Geographically, the global biosimilars market is dominated by Europe, followed by Asia-Pacific, Rest of

the World (RoW), and North America. However, the Asia-Pacific region is likely to witness the highest

growth rate during the forecast period. Factors such as developing healthcare infrastructure, presence of

a large patient population, increasing funding/investments for the development of biosimilars, and growing

focus of both international and domestic players on emerging Asia-Pacific countries are stimulating the

growth of the market in this region.

The key players in the global market include Sandoz International GmbH (Germany), Hospira, Inc. (U.S.),

Teva Pharmaceutical Industries Ltd. (Israel), Dr. Reddy’s Laboratories (India), Biocon Limited (India),

Mylan, Inc. (U.S.), Amgen (U.S.), Celltrion Inc. (South Korea), Roche Diagnostics (Switzerland), and

Merck KGaA (Germany).


Biosimilars market size estimation

About MarketsandMarkets

MarketsandMarkets is the largest market research firm worldwide in terms of annually published premium

market research reports. Serving 1700 global fortune enterprises with more than 1200 premium studies in

a year, M&M is catering to a multitude of clients across 8 different industrial verticals. We specialize in

consulting assignments and business research across high growth markets, cutting edge technologies

and newer applications. Our 850 fulltime analyst and SMEs at MarketsandMarkets are tracking global

high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive

collaboration with the clients to identify new opportunities, identify most important customers, write

"Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and

its competitors.

M&M’s flagship competitive intelligence and market research platform, "RT" connects over 200,000

markets and entire value chains for deeper understanding of the unmet insights along with market sizing

and forecasts of niche markets. The new included chapters on Methodology and Benchmarking

presented with high quality analytical infographics in our reports gives complete visibility of how the

numbers have been arrived and defend the accuracy of the numbers.

We at MarketsandMarkets are inspired to help our clients grow by providing apt business insight with our

huge market intelligence repository.

Contact:

MarketsandMarkets

701 Pike Street

Suite 2175, Seattle,

WA 98101, United States

Telephone No : 1-888-600-6441

Email: [email protected]


  • Login